식욕억제제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 투여 경로별, 유통 채널별, 지역별, 경쟁별(2019-2029년)

Global Anorexiants Market was valued at USD 924.67 million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.84% through 2029. The Global Anorexiants Market constitutes a dynamic segment within the pharmaceutical industry, focusing on the development and distribution of medications known as anorexiants. Anorexiants are pharmaceuticals designed to suppress appetite and facilitate weight loss in individuals grappling with obesity. They serve as pivotal components of comprehensive weight management programs. Anorexiants primarily act on the central nervous system, targeting neurotransmitters and signaling pathways involved in hunger and satiety regulation. The predominant class of anorexiants is stimulants, which heighten the release of specific brain chemicals like norepinephrine and dopamine. These neurotransmitters modulate the appetite control center, curbing hunger sensations and promoting feelings of fullness. For instance, Phentermine, a commonly prescribed anorexiant, is a sympathomimetic amine that triggers the release of norepinephrine, thereby inducing appetite suppression through hypothalamic action. Conversely, other anorexiants like Orlistat function by impeding dietary fat absorption, thereby reducing calorie intake.

The Global Anorexiants Market is propelled by the escalating prevalence of obesity and its associated health complications such as diabetes and cardiovascular diseases. Lifestyle modifications, sedentary behaviors, and poor dietary habits contribute to the heightened demand for weight management remedies. Anorexiants, when administered and monitored under healthcare professional guidance, offer a pharmaceutical avenue to support weight loss endeavors. Nonetheless, anorexiants present challenges. Potential side effects like increased heart rate, insomnia, and elevated blood pressure necessitate careful consideration. Also, there exists a risk of dependence and misuse, calling for judicious prescription practices.

In recent years, the market has witnessed advancements in the development of novel anorexiants boasting improved safety profiles and mechanisms of action. Reflecting ongoing efforts to address the global obesity epidemic, the Global Anorexiants Market plays a pivotal role in enhancing the overall health and well-being of individuals seeking effective weight management solutions. As research persists and innovative formulations emerge, the market stands poised to contribute significantly to the multifaceted approach to combating obesity and mitigating associated health risks.

Key Market Drivers

Rising Prevalence of Obesity

The rising prevalence of obesity globally is a significant factor propelling the growth of the Anorexiants Market. Obesity has reached epidemic proportions, with a substantial increase in the number of individuals classified as overweight or obese. Unhealthy dietary habits, sedentary lifestyles, and a lack of physical activity contribute to this alarming trend. Obesity is a multifaceted health concern associated with various co-morbidities, including diabetes, cardiovascular diseases, and hypertension. The substantial health risks linked to excess body weight have heightened awareness among individuals, healthcare professionals, and policymakers about the urgent need for effective weight management strategies. As individuals grapple with the challenges of obesity and its associated health consequences, there is a growing demand for interventions that can aid in weight loss. Anorexiants play a crucial role in this context by suppressing appetite and promoting weight reduction. These medications become a viable option for individuals struggling to achieve and maintain a healthy weight through lifestyle modifications alone. The prevalence of obesity is not limited to specific regions; it affects populations worldwide. This global health challenge has spurred the pharmaceutical industry to develop and provide effective pharmacological solutions, contributing to the expansion of the Anorexiants Market. Governments, healthcare organizations, and public health initiatives are increasingly recognizing the impact of obesity on overall health and well-being. As a result, there is a collective effort to address the root causes of obesity and provide accessible and effective treatments, including anorexiants, to individuals seeking assistance in their weight management journey. The rising tide of obesity underscores the relevance and importance of the Anorexiants Market in addressing this global public health crisis.

Health Concerns Associated with Obesity

Health concerns associated with obesity play a pivotal role in driving the demand for anorexiants within the global market. Obesity is not merely a cosmetic issue; it is intricately linked to a spectrum of serious health conditions, amplifying the urgency to address weight-related issues comprehensively. Obesity is a known risk factor for the development of type 2 diabetes, cardiovascular diseases, hypertension, and metabolic disorders. The accumulation of excess body fat can lead to insulin resistance, disrupting glucose metabolism and increasing the likelihood of diabetes. Cardiovascular complications, including heart disease and stroke, are heightened in individuals with obesity due to factors such as elevated blood pressure and cholesterol levels. The strain on joints and musculoskeletal structures in obese individuals often leads to conditions like osteoarthritis, impacting mobility and overall quality of life.

Also, obesity is associated with an increased risk of certain cancers, respiratory disorders, and mental health issues such as depression and anxiety. The recognition of these severe health implications has prompted individuals, healthcare professionals, and policymakers to actively address the root causes of obesity and seek effective interventions. Anorexiants emerge as a pharmacological solution by curbing appetite and aiding in weight loss, thereby addressing the health concerns associated with obesity. The Anorexiants Market aligns with the collective effort to mitigate the impact of obesity-related health conditions. As awareness grows regarding the multifaceted health risks linked to excess body weight, anorexia becomes integral in the broader strategy of promoting healthier weights and reducing the burden of obesity-related diseases. This heightened awareness underscores the essential role of anorexiants in the overall management of obesity and associated health concerns on a global scale.

Advancements in Research and Development

Advancements in research and development (R&D) are pivotal in shaping the landscape of the global Anorexiants Market, contributing to the evolution of more effective and safer weight management solutions. The pharmaceutical industry is actively engaged in exploring innovative approaches and formulations within this market segment. Researchers are focusing on developing novel anorexiants with improved mechanisms of action, targeting specific pathways involved in appetite regulation. These advancements aim to enhance the efficacy of anorexiants while minimizing potential side effects. New formulations are designed to provide a more targeted and personalized approach to weight management. One notable area of R&D is the exploration of combination therapies that leverage synergies between different medications. Combining anorexiants with complementary mechanisms can offer a comprehensive and multifaceted approach to weight loss, potentially leading to better outcomes for individuals seeking pharmacological interventions. Additionally, there is a growing emphasis on understanding the neurobiological aspects of appetite control. Researchers are delving into the intricate neural pathways and neurotransmitter systems involved in hunger and satiety, aiming to identify new drug targets for the development of next-generation anorexiants. The use of cutting-edge technologies, such as artificial intelligence and machine learning, is also becoming increasingly prevalent in drug discovery and development. These technologies assist in analyzing vast datasets to identify potential drug candidates, predict their efficacy, and optimize treatment regimens. As the Anorexiants Market advances, ongoing research efforts contribute to a deeper understanding of obesity's biological underpinnings and the development of more tailored and efficient pharmacological interventions. These advancements underscore the commitment of the pharmaceutical industry to address the global challenges posed by obesity and improve the overall efficacy and safety of anorexiants in the pursuit of healthier weights.

Key Market Challenges

Side Effects and Safety Concerns

Community engagement and health education play a pivotal role in the Global Anorexiants Market, serving as key components for the success of interventions aimed at eliminating trachoma, a preventable cause of blindness. These initiatives focus on empowering communities, raising awareness, and promoting sustainable behavioral changes. Side effects and safety concerns are critical considerations in the global Anorexiants Market, shaping the utilization and acceptance of weight management medications. Anorexiants, designed to suppress appetite and aid in weight loss, often come with a range of potential side effects that demand careful evaluation. Common side effects include increased heart rate, insomnia, elevated blood pressure, and dry mouth. These effects can vary in intensity among individuals and may contribute to concerns about the overall safety of anorexiants. Balancing the benefits of weight loss with the potential risks of adverse reactions becomes a crucial aspect of prescribing and using these medications. Safety concerns are particularly pronounced with anorexiants that have stimulant properties. The risk of dependence and abuse, coupled with the potential for cardiovascular issues, underscores the need for vigilant monitoring and controlled usage. Striking a balance between achieving effective weight loss and minimizing the risk of side effects poses a challenge for healthcare professionals. Regulatory bodies closely scrutinize anorexiants to ensure their safety profiles align with established standards. Manufacturers must navigate stringent approval processes, providing extensive safety data before these medications reach the market. Individual responses to anorexiants vary, adding complexity to safety considerations. Tailoring treatment plans to accommodate these variations and ensuring that patients are well-informed about potential side effects and risks is crucial. In the Anorexiants Market, ongoing research and development efforts focus on mitigating side effects and enhancing safety profiles. Advances in formulation and drug delivery seek to maintain efficacy while minimizing adverse reactions, addressing safety concerns to improve the overall risk-benefit profile of anorexiants in the pursuit of effective and safe weight management solutions.

Individual Variability in Response

Individual variability in response poses a significant challenge in the global Anorexiants Market, where the effectiveness of weight management medications can vary widely among individuals. Anorexiants, designed to suppress appetite and promote weight loss, may yield different outcomes based on factors such as genetics, metabolism, and overall health status. The diversity in individual responses to anorexiants complicates the establishment of standardized treatment protocols. What works effectively for one person may not produce the same results for another, making it challenging for healthcare professionals to predict and optimize outcomes. Factors influencing variability include genetic predispositions, hormonal fluctuations, and underlying health conditions. The complexity of individual responses also extends to the occurrence of side effects. While some individuals may experience minimal adverse reactions, others may be more susceptible to certain side effects, leading to challenges in achieving a balance between therapeutic benefits and potential drawbacks. Tailoring anorexiant treatments to accommodate individual variability requires a personalized medicine approach. Understanding the genetic and metabolic factors influencing drug response can aid in developing more targeted and effective interventions. Advances in pharmacogenomics, which study how genetic variations impact drug responses, hold promise in providing insights into individualized treatment plans. Healthcare professionals face the challenge of navigating this variability to optimize treatment outcomes while minimizing potential risks. Ongoing research in the Anorexiants Market aims to unravel the complexities of individual responses, paving the way for more precise and personalized approaches to weight management. In doing so, the industry strives to enhance the overall efficacy and safety of anorexiants, acknowledging and addressing the diverse nature of individual reactions to these medications.

Key Market Trends

Increased Emphasis on Combination Therapies

The global Anorexiants Market is witnessing a notable trend with an increased emphasis on combination therapies, marking a shift towards more comprehensive approaches to weight management. Combination therapies involve the simultaneous use of multiple medications, each targeting different aspects of appetite regulation and weight loss. This trend stems from the recognition that obesity is a complex condition influenced by various physiological factors, and addressing these factors synergistically may lead to more effective outcomes. Combining anorexiants with distinct mechanisms of action allows for a multifaceted approach to weight loss. For example, a combination of medications may include appetite suppressants, metabolic enhancers, and fat absorption inhibitors. This strategy aims to optimize therapeutic benefits while mitigating the risk of side effects associated with individual medications. The trend towards combination therapies aligns with the broader shift in healthcare towards personalized and precision medicine. Tailoring treatment regimens to individual patient profiles, considering factors such as genetics and metabolic characteristics, enhances the potential for successful weight management.

Also, combination therapies may address the challenges of individual variability in response to anorexiants, providing a more adaptable and patient-centric approach. Pharmaceutical companies are actively exploring innovative combinations and conducting research to identify synergies that can lead to enhanced efficacy, improved patient adherence, and a more sustained impact on weight loss. As the Anorexiants Market continues to evolve, the increased emphasis on combination therapies reflects a commitment to developing more nuanced and effective solutions for individuals struggling with obesity, contributing to a comprehensive and personalized paradigm in weight management.

Rise of Non-Prescription Alternatives

The global Anorexiants Market is witnessing a significant trend with the rise of non-prescription alternatives, signaling a shift towards accessible and perceived safer options for weight management. This trend encompasses a variety of over-the-counter (OTC) products, including herbal supplements, natural remedies, and non-prescription formulations, which individuals can obtain without a doctor's prescription. Consumers are increasingly seeking non-prescription alternatives as they often perceive them to be more convenient, cost-effective, and associated with fewer potential side effects compared to prescription anorexiants. This trend aligns with a broader movement towards self-care and proactive health management. Herbal supplements, often derived from plant extracts, are gaining popularity in the non-prescription segment of the Anorexiants Market. Ingredients like green tea extract, Garcinia Cambogia, and hoodia gordonii are among those marketed for their potential appetite-suppressing or metabolism-boosting properties. The rise of non-prescription alternatives is also fueled by a growing interest in natural and holistic approaches to weight management. Consumers, motivated by a desire for perceived safety and a preference for more organic solutions, are exploring these options as complementary or standalone interventions. However, it's essential to note that the efficacy and safety of non-prescription alternatives can vary, and their regulation may differ across regions. As the trend continues, regulatory bodies are likely to play a crucial role in ensuring the transparency, quality, and safety of these products. Pharmaceutical companies are responding to this trend by diversifying their product portfolios to include both prescription and non-prescription offerings, providing consumers with a broader spectrum of choices for weight management based on individual preferences and needs. The rise of non-prescription alternatives underscores the evolving dynamics in the Anorexiants Market, reflecting the increasing demand for diverse and accessible solutions to address the global concern of obesity.

Segmental Insights

Route Of Administration Insights

Based on route of administration, oral anorexiants segment dominated the Global Anorexiants Market in 2023. This is because of its convenience, widespread acceptance, and ease of administration. Oral anorexiants, typically in pill or capsule form, offer a non-invasive and user-friendly approach to appetite suppression and weight management. This mode of administration aligns with patient preferences, promoting better adherence to treatment regimens. Additionally, oral medications are easily scalable for mass production, facilitating broad market availability. The simplicity of oral administration, coupled with its effectiveness in appetite control, contributes to the dominance of the oral segment in the global market for anorexiants.

Regional Insights

In 2023, North America emerged as the predominant market for anorexiants, primarily driven by the escalating prevalence of obesity-related complications in the region. The surge in obesity is evident across all age groups, as indicated by the 2017-2020 NHANES study, which reported a growing prevalence of obesity among children and adolescents, with approximately 20% of youngsters aged 2 to 19 in the United States classified as obese. At a national level, 41.9% of adults were grappling with obesity in 2023. The market's momentum is further propelled by the presence of major industry players and a significant target population with disposable income in the U.S., setting the stage for continued market growth in the forecast period.

Key Market Players

VIVUS LLC.

Arena Pharmaceuticals, Ltd.

F. Hoffmann-La Roche Ltd.

Novo Nordisk A/S

Currax Pharmaceuticals LLC.

AbbVie Inc.

ReShape Lifesciences Inc.

Ethicon Inc. (Subsidiary of Johnson & Johnson).

Sanofi S.A.

Medtronic Plc.

Report Scope:

In this report, the Global Anorexiants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anorexiants Market, By Distribution Channels :

Online Pharmacy Retail Pharmacy Hospital Pharmacy

Anorexiants Market, By Route of Administration:

Subcutaneous Anorexiants Oral Anorexiants

Anorexiants Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anorexiants Market.

Available Customizations:

Global Anorexiants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anorexiants Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Subcutaneous Anorexiants, Oral Anorexiants)
  • 5.2.2. By Distribution Channels (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Distribution Channels
  • 5.3.3. By Region

6. Asia Pacific Anorexiants Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Distribution Channels
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Anorexiants Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Distribution Channels
  • 6.3.2. India Anorexiants Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Distribution Channels
  • 6.3.3. Australia Anorexiants Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Distribution Channels
  • 6.3.4. Japan Anorexiants Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Route of Administration
      • 6.3.4.2.2. By Distribution Channels
  • 6.3.5. South Korea Anorexiants Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Route of Administration
      • 6.3.5.2.2. By Distribution Channels

7. Europe Anorexiants Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Distribution Channels
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Anorexiants Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Distribution Channels
  • 7.3.2. Germany Anorexiants Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Distribution Channels
  • 7.3.3. Spain Anorexiants Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Distribution Channels
  • 7.3.4. Italy Anorexiants Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Distribution Channels
  • 7.3.5. United Kingdom Anorexiants Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Distribution Channels

8. North America Anorexiants Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Distribution Channels
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Anorexiants Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Distribution Channels
  • 8.3.2. Mexico Anorexiants Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Distribution Channels
  • 8.3.3. Canada Anorexiants Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Distribution Channels

9. South America Anorexiants Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Distribution Channels
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Anorexiants Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Distribution Channels
  • 9.3.2. Argentina Anorexiants Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Distribution Channels
  • 9.3.3. Colombia Anorexiants Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Distribution Channels

10. Middle East and Africa Anorexiants Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Distribution Channels
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Anorexiants Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Distribution Channels
  • 10.3.2. Saudi Arabia Anorexiants Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Distribution Channels
  • 10.3.3. UAE Anorexiants Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Distribution Channels
  • 10.3.4. Egypt Anorexiants Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Route of Administration
      • 10.3.4.2.2. By Distribution Channels

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Anorexiants Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. VIVUS, LLC.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Arena Pharmaceuticals, Ltd.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Novo Nordisk A/S
• 15.5. Currax Pharmaceuticals LLC
• 15.6. AbbVie Inc.
• 15.7. ReShape Lifescience Inc.
• 15.8. Ethicon Inc. (Subsidiary of Johnson & Johnson).
• 15.9. Sanofi S.A.
• 15.10. Medtronic Plc

16. Strategic Recommendations

17. About Us & Disclaimer